DelveInsight’s “Leber Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Leber Hereditary Optic Neuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Leber Hereditary Optic Neuropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Leber Hereditary Optic Neuropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Leber Hereditary Optic Neuropathy: An Overview
Leber Hereditary Optic Neuropathy (LHON) manifests as bilateral, painless, and gradual central vision impairment typically striking individuals in their early adulthood. Initially, symptoms often appear in one eye before affecting the other eye a few weeks later. Although uncommon, some cases may present additional neurological manifestations such as peripheral neuropathy, postural tremors, nonspecific myopathy, and movement disorders.
The underlying cause of LHON lies in mutations within mitochondrial DNA, with inheritance occurring exclusively through maternal lines. The incidence of visual impairment due to LHON stands at approximately 1:50,000 individuals. Interestingly, many carriers of the mutation remain asymptomatic throughout their lives, with males exhibiting a notably higher risk of vision loss compared to females, at a ratio of about four to five times. Typically, symptoms emerge during the early adult years, and if vision loss occurs, it usually transpires before the age of 40.
The acute phase of LHON is characterized by central vision loss, presenting symptoms like blurring and diminished color perception. Usually, one eye is affected initially, followed by the other eye within a span of two to three months. Subsequently, the atrophic phase ensues, marked by bilateral optic atrophy leading to permanent blindness.
LHON is diagnosed based on ophthalmologic findings, which include specialized visual testing. The testing involves dilated fundus examination to identify characteristic changes in the optic disc and vascular changes during the acute phase, visual fields, electrophysiologic studies, and imaging, particularly OCT. Molecular genetic testing for mitochondrial genes associated with LHON can be used to confirm diagnosis.
Leber Hereditary Optic Neuropathy Market Key Facts
- According to Shemesh et al. (2022), Leber’s hereditary optic neuropathy (LHON) is estimated to be the most frequent mitochondrial disease with a prevalence ranging from 1 in 27,000 in North East England to 1 in 45,000 in a meta-analysis of reports in the European population. It has a strong male preponderance (80% to 90%), and the usual age at onset is between 15 and 35 years.
- As per the NORD (2019), the prevalence of visual loss from LHON is approximately 1:50,000 people. Many carriers never suffer significant visual loss; males are about four to five times more likely than females to lose vision and be affected.
- As per Man et al. (2016), LHON is characterized by a marked gender bias, with males more likely to become affected than females.
- According to a national epidemiological survey on LHON conducted by Takano et al. (2022) in Japan, the number of newly diagnosed patients with LHON in 2019 was estimated to be 69, and the total number of LHON patients in Japan was estimated to be 2400, with a prevalence similar to other countries.
Leber Hereditary Optic Neuropathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Leber Hereditary Optic Neuropathy pipeline therapies. It also thoroughly assesses the Leber Hereditary Optic Neuropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Leber Hereditary Optic Neuropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Leber Hereditary Optic Neuropathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Leber Hereditary Optic Neuropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Leber Hereditary Optic Neuropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Leber Hereditary Optic Neuropathy Epidemiology, Segmented as –
- Total Prevalent Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
- Diagnosed Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
- Gender-specific Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
- Mutation-specific Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
Leber Hereditary Optic Neuropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Leber Hereditary Optic Neuropathy market or expected to be launched during the study period. The analysis covers the Leber Hereditary Optic Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Leber Hereditary Optic Neuropathy drugs based on their sale and market share.
The report also covers the Leber Hereditary Optic Neuropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Leber Hereditary Optic Neuropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Leber Hereditary Optic Neuropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Leber Hereditary Optic Neuropathy Therapeutics Analysis
Currently, Raxone (idebenone) is the only available medicinal product authorized to treat LHON within the European Union. Brimonidine, nutritional supplements, and ubiquinone analogs are the potential treatment options. Along with these therapies, alternative therapies such as steroids and immunosuppressants such as cyclosporine A are being tried in the treatment of LHON. Currently, the most exciting potential means of treating LHON are within the field of gene therapy.
To further improve the treatment scenario, several leading companies are actively engaged in the development of treatments for Leber’s hereditary optic neuropathy (LHON). Among these, GenSight Biologics stands out with its LHON drug candidates, which are currently in the most advanced stage of development, namely the preregistration phase. This signifies a significant milestone in the journey towards providing effective therapies for individuals affected by LHON, highlighting the dedication and progress within the pharmaceutical industry to address this genetic disorder.
Leber Hereditary Optic Neuropathy Companies Actively Working in the Therapeutics Market Include
Several prominent companies are actively engaged in the development of therapies for Leber’s hereditary optic neuropathy (LHON). These companies include GenSight Biologics, which stands out with its LHON drug candidates currently in the most advanced stage of development. Additionally, Neurophth Therapeutics, Mitotech, Stealth BioTherapeutics, Fortify Therapeutics, and Neuroptika are also among the front-runners in this endeavor. Their collective efforts underscore the commitment and progress within the pharmaceutical industry to address LHON, a genetic disorder impacting individuals worldwide.
Emerging and Marketed Leber Hereditary Optic Neuropathy Therapies Covered in the Report Include:
- GS010 (lenadogene nolparvovec): GenSight
- Elamipretide: Stealth Biotherapeutics
- NFS-02: Neurophth Therapeutics
- Elamipretide: Stealth BioTherapeutics Inc.
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Leber Hereditary Optic Neuropathy Competitive Intelligence Analysis
4. Leber Hereditary Optic Neuropathy Market Overview at a Glance
5. Leber Hereditary Optic Neuropathy Disease Background and Overview
6. Leber Hereditary Optic Neuropathy Patient Journey
7. Leber Hereditary Optic Neuropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Leber Hereditary Optic Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Leber Hereditary Optic Neuropathy Unmet Needs
10. Key Endpoints of Leber Hereditary Optic Neuropathy Treatment
11. Leber Hereditary Optic Neuropathy Marketed Therapies
12. Leber Hereditary Optic Neuropathy Emerging Drugs and Latest Therapeutic Advances
13. Leber Hereditary Optic Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Leber Hereditary Optic Neuropathy Market Outlook (In US, EU5, and Japan)
16. Leber Hereditary Optic Neuropathy Companies Active in the Market
17. Leber Hereditary Optic Neuropathy Access and Reimbursement Overview
18. KOL Views on the Leber Hereditary Optic Neuropathy Market
19. Leber Hereditary Optic Neuropathy Market Drivers
20. Leber Hereditary Optic Neuropathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Meniere’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Meniere’s Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Meniere’s Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research